A number of preclinical studies have shown the adenoassociated virus (AAV) to be an efficient vehicle for gene therapy. Clinical studies successfully demonstrated its potential for in vivo gene transfer. The complexity of hostvector interactions when progressing from small to large animal models, and eventually to humans, has impeded translation of AAV technology to the clinic. One approach to address this complexity has been to explore the biological characteristics of variations in AAV capsid structure. Initial strategies characterized the naturally occurring capsid variants from mammalian species. The structural and functional knowledge gathered on these natural AAV variants as vectors has led to the first series of second-generation vectors that aim at specifically improving certain properties by rational design of the capsid. A third exciting approach uses directed evolution to isolate vectors that are able to overcome selective pressures applied in the laboratory and thereby steer the capsid to evolve toward improved functionality.
Introduction
A wild-type adeno-associated virus (AAV) particle contains a single-stranded DNA genome and a capsid comprised of three structural Cap proteins (VP1, -2 and -3). The majority of its T ¼ 1 icosahedral architecture is made up by the 60 kDa VP3 proteins. For every 10 VP3 molecules, one VP1 and one VP2 capsid monomer is anchored in the particle structure by the C terminus that is structurally identical to the VP3 monomer. 1 Adeno-associated virus is endemic in primate populations and has been isolated from various other mammalian sources. In the absence of an infection with a helper virus, the viral genome is thought to reside in a latent state in the nucleus. 1 Several sources have served as substrates for the isolation of novel AAVs; the first six primate serotypes were identified as contaminants of adenoviral preparations whereas others were characterized from clinical samples or tissue sources (reviewed in Gao et al. 2 ). The molecular cloning of AAV2, 3 the most characterized AAV serotype to date, has set the stage for the generation of an AAV particle that is replication defective even in the presence of help. In most vector designs, only the AAV2 inverted terminal repeats are retained as viral elements as they flank the transgene cassette. For vector production, the viral sequences for rep and cap genes are provided in trans (reviewed in Grieger et al. 4 ). Transencapsidation allows the packaging of capsids from distinct serotypes onto AAV2 inverted terminal repeat-flanked expression cassettes in the context of the AAV2 proteins for replication (Rep) . This generated a versatile system to evaluate the impact of the capsid on AAV transduction by maintaining an identical transgenic genome in the context of distinct capsid particles. 5, 6 Impetus for the search for alternative capsids
Various motifs have propelled the quest for alternative AAV capsids. Although AAV2 was proven to be efficient by in vitro transduction, this serotype was limited in its in vivo transduction efficiency of important tissues and/ or cell types. In the liver, for example, Kay and colleagues demonstrated that only B5% of hepatocytes can become stably transduced by AAV2. 7 Certain therapeutic target organs are essentially refractory to AAV2 transduction, limiting the range of viable applications. 8 The capsid is the primary interface between the host and the vector genome. It is presumed to determine cell and tissue tropism. Indeed, the specificity and efficiency of transduction and the breadth of biodistribution of the AAV particle are dependent on the vector capsid. 9 For example, in several animal models, AAV4 targets the retinal pigment epithelium following subretinal delivery more specifically than AAV2. 10 In the mouse lung, AAV5 and AAV6 target cells primarily of the conducting airway, whereas AAV9 has a more alveolar tropism. 11, 12 In contrast, for certain applications (for example, various forms of muscular dystrophy), a wide distribution of transduction is desired. For mouse, systemic muscle transduction can be achieved with AAVs 6, 8 and 9. [13] [14] [15] The propensity of certain AAVs to cross or bypass certain anatomical barriers such as the brain-blood barrier or the vascular endothelium might also be related to the composition of the capsid. 13, 14 Another important concern limiting AAV clinical application is the prevalence of neutralizing antibodies (NABs) in human populations. Even at low levels, these NABs can significantly impact on in vivo transduction efficiency and efficacy. 16, 17 Clearly, their impact will depend on the route of administration, anatomical barriers and other factors that can limit the exposure of the vector to circulating NAB toward the capsid. In an extensive screening of human sera originating from individuals in North America, Africa, Australia and Europe, NAB to AAV2 ranged between 29 and 59% of individual samples, depending on their geographical origin. 18 Critical to the safety and efficacy of any gene therapy is the control of the immunological response that ensues following vector administration. The innate immune response to the AAV capsid has received limited attention, largely due to the minimal responses that AAV2 elicits. 19 Whether different capsid vectors generate distinct pro-inflammatory responses is still an open question. One possible insight in this area is provided by the different adaptive immune responses that result from administration with distinct AAVs. 20, 21 Indeed, the pro-inflammatory context may define the qualitative nature of the adaptive immune responses toward transgene product and/or capsid. To achieve stable expression and minimize toxicity at the target organ, neutralizing or cytotoxic immune responses toward the transgene product need to be avoided. Antibody responses to secreted transgene products can inhibit their levels in circulation and their therapeutic effect. 22 The humoral response to vector administration is preferred to be minimal in an application that requires repetitive dosing and may also be serotype dependent. 11 Conversely, the immunogenic potential of AAV would be beneficial in vaccine applications.
The capsid structure can play a role in the production yield and the feasibility of the downstream processing of the vector in terms of purification and formulation. [23] [24] [25] To that extent, capsid modifications might facilitate AAV vector process development. It is also conceivable that the physical properties of a vector preparation, such as vector stability and storage conditions, may also be influenced by the capsid structure.
Natural diversity as a source of novel capsids
Initial AAV vectors were derived from AAV serotypes 1-6. Data indicated a substantial impact of capsid composition on vector performance. 26 This sparked an effort by multiple groups to isolate and/or characterize additional AAV capsids. Two general approaches were considered. In one approach, the methodologies were preferentially aimed at identifying natural AAV isolates from human or non-human primate species. [27] [28] [29] [30] [31] The working hypothesis assumed these primate viruses are able to transduce human tissue yet are sufficiently distinct from the known human serotypes to confer unique biology for gene therapy applications. In a second approach, AAVs from more distantly related hosts were evaluated for their use as vectors for gene therapy. [32] [33] [34] [35] As human AAV vectors were permissive in a wide range of hosts including mice and dogs, it was speculated that the reverse would hold true as well. AAVs isolated from species other than humans might be more effective in circumventing issues resulting from pre-exposure to the endemic AAV in human populations.
The novel avenues that this renaissance in AAV vectorology brought about are extensively reviewed elsewhere. 2, 26, 36 In general terms, current data from animal models indicate that AAVs from primate origin have a wide tropism and enhanced gene transfer efficiency in some therapeutic targets when compared with the vector systems characterized earlier. Limited data based on vectors isolated from more distantly related hosts have suggested unique transduction properties but data in mice indicate a more modest gene transfer efficiency in comparison to some of the more efficient primate vectors. [32] [33] [34] [35] Current data indicate that a significant seroprevalence to most primate AAVs exists in human populations. 18 A limited number of studies with more distantly related AAVs indicate that the corresponding vectors evade a serological recognition in human sera more effectively than primate-derived AAVs. 18, 37 The large numbers of different AAV capsids provide a challenge in identifying and characterizing which isolates or clones to develop as vectors and which one of those to progress to the clinic. An initial overview of the diversity and the mechanisms through which it arose is reviewed in several phylogenetic and taxonomic reports elsewhere.
2,28,38 AAV's evolutionary biology provides evidence for viral recombination and for a significant error rate during replication-two properties that were thought to be unique to RNA viruses. Primate AAV isolates cluster into six monophylic clades, some of which are represented by a known AAV serotype. Current data indicate an overall structural, serological and functional grouping of the members within a clade. However, not all members of a single clade are necessarily identical in terms of biological phenotype. For example, within clade B represented by AAV2, several groups have isolated capsids that do not have AAV2's propensity to bind heparin sulfate proteoglycan. 21, 31 A more extensive structure-function analysis was able to eliminate some redundancy among the primate AAV isolates by establishing a vector library that aimed to be representative of the majority of the structural diversity within the AAV space. 39 Ideally, a more thorough understanding of the biology of the wildtype viruses may steer the selection of the AAV capsid to use for gene therapy. One limitation in this respect is that most studies were based on molecular characterization of cap only, whereas natural variation in other viral components might have been overlooked with this approach. For example, comparing the tissue source of latent AAV genome with the corresponding vector tissue tropism after gene transfer shows little or no correlation 28, 38 (G Gao and JM Wilson, unpublished data). Thorough bioinformatics approaches might provide descriptive and eventually predictive tools to correlate structure with vector function more efficiently. Even though advances have been made in understanding the structure-function correlations, the empirical evaluation of the different capsid vectors in vivo to date is the most AAV vector capsid for gene therapy LH Vandenberghe et al effective method to determine the most appropriate capsid for a certain application.
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Second-generation AAV vectors by rational design
A greater knowledge of the structural diversity of AAV has paved the road for engineering of the capsid. Functional analysis of sequence diversity and mutagenesis studies has mapped several structural constraints and determinants of AAV's biology. [42] [43] [44] [45] [46] [47] The increasing number of structural models of AAV serotypes provides not only an insight in the physical underpinning of AAV biology but also serves as a template to model and predict the impact of specific capsid modifications. [48] [49] [50] Directly inserting known ligands into the AAV capsid permits the retargeting to cell types or tissues with a low affinity for the wild-type vector. 44 Some of these approaches aim to achieve transductional retargeting to the desired target as well as the removal of endogenous tropism to limit biodistribution and/or improve the specificity of transduction. 51 Similar techniques have been described to insert an affinity ligand that allows chromatography for high-resolution single-step purification of a vector preparation. 52 Preserving the integrity and the biology of both ligand and transducing vector is a significant challenge in these approaches.
Another type of vector engineering builds on the emerging body of knowledge on structure-function relationships. Indeed, by delineating determinants of vector function on the capsid, AAV vector design and tailoring to remove or add particular properties may be possible. By transferring these elements into a different context, one could potentially coalesce beneficial properties of various AAV types onto a single particle. One such approach takes advantage of the conserved nature of the VP3 monomer on a three-dimensional level. By cotransfecting capsids of two distinct serotypes, a mosaic particle can be generated that is cross-dressed with different capsid monomers. 53 In select cases, this technique not only allows an additive effect of the properties of the two parental capsid elements but sometimes also yields a particle with synergetic or novel biology. Intramolecular modifications that selectively incorporate residues or domains from one AAV isolate to another have been shown to create particles with hybrid biology in terms of tropism. 54 More recently, we have demonstrated that the ablation or addition of a heparin-binding motif modulates the antigenicity of the particle. 21 Others have shown similar modifications also to beneficially alter in vivo biodistribution and vector tropism for certain applications. 55, 56 Directed evolution to overcome host restriction An exciting advance in the field is the one that combines rational design strategies while employing evolutionary selection. These strategies generally start by generating a diverse library of capsid molecules through combinatorial methodology. 57 This has been done for small targeting peptides in known capsid-insertion sites within the context of a single AAV serotype to identify higher affinity ligands for redirecting tropism. 58 Others have generated diversity within the entire capsid by mixing and matching fragments of natural isolates and/or introducing structural variation through error-prone PCR techniques. [59] [60] [61] The combinatorial high-throughput aspects of these techniques eventually yield molecular diversity of a large magnitude. In a second phase, the fitness of these viruses is tested by applying one or more selective pressures toward the property that one aims at improving. These directed evolution experiments often require iterative steps of selection and therefore require the use of replicating (that is, wild type) virus rather than recombinant replication-defective AAV. The selective pressure eventually leads to the emergence of a smaller population of capsid with more fit and therefore desired properties. For this strategy to succeed, increased fitness of the replicating virus needs to translate to increased fitness within a replication-deficient vector system.
To propagate the selective advantage that a novel capsid protein provides, it is critical for this strategy that each particle in the combinatorial pool physically links capsid gene and capsid protein. With packaging signals only provided by the inverted terminal repeat regions and cross-mobilization of genomes occurring, this may not always be achieved and therefore result in the aspecific loss of vector particles of potential interest. Carefully designed strategies (for example, working at low DNA copy numbers per cell) have been proposed to address this issue. 62 One advantage of directed evolution approaches is that a full understanding of the structurefunction biology is not required for successful capsid modifications. The most important component in this process is the relevance of the selective pressure conditions to the clinical application. The ability to move these from the current stage of in vitro selection to an in vivo setting will empower this technology even more. Our limited understanding of permissivity and replication of AAV in the most commonly used animal models makes this technically daunting.
Current status, unresolved questions and limitations
For obvious reasons, the natural serotypes and isolates of AAV have progressed furthest in the preclinical and clinical trajectory. One second-generation capsid, namely AAV2.5, a vector based on AAV2 with five modifications in the capsid structure to enhance transduction and reduce susceptibility to NAB, is the vector of choice in an ongoing muscular dystrophy clinical study (Table 1) .
Some receptors for AAV serotypes have been identified but generally do not fully predict the differences in transduction efficiency and selectivity, particularly in vivo. [74] [75] [76] [77] 105 For some serotypes, the rate-limiting steps lie at a post entry level and relate to differential endosomal processing and/or mechanisms of uncoating, particle stability or vector genome release from the capsid 115, 116 (Table 1 ). The ability of AAV vectors to have a therapeutic and long-lasting effect has been established in several proofof-concept studies with AAV2 in models of inherited diseases. 97, 117 In addition, in several small animal disease models, novel serotypes have demonstrated therapeutic efficacy. The ability to translate these findings to large AAV vector capsid for gene therapy LH Vandenberghe et al animal models and eventually humans has been particularly challenging to assess. Most of the large animal data have been gathered with AAV2 and more recently also for other naturally occurring AAV serotypes such as 5, 6, 7 and 8 ( Table 1) . Few studies document a side-byside quantitative comparison of the serotypes in both mice and a large animal model. The approximate eightfold difference in mouse between AAV2 and AAV8 was reduced to 1.5-to 4.3-fold in dogs for a liver-secreted canine FIX transgene product. 109 Other data from a dog model suggest an equally limited advantage of the AAV6 and -8 serotypes when compared with AAV2 in liver-directed gene transfer approaches. 108 In non-human primate experiments with FIX, a reduced or absent differential was observed between serotypes in comparison with the murine model. 118 When a selfprotein was used as a reporter, alternative serotypes did demonstrate a substantial advantage in rhesus macaques. 94 These studies highlighted a biphasic expression pattern over time as well as a transgene product dependence of the serotype differences. In addition to the limited group sizes of these experiments and the difficulty controlling all possible biases (for example, sex and age), non-human primates are likely to be preexposed to wild-type AAV. Moreover, AAV7 and AAV8 have a much greater prevalence than AAV2 in these animal populations, whereas the reverse is true in humans. 27 For these studies, all animals were prescreened for the absence of NAB to the AAV capsid in a sensitive inhibition of infectivity assay. However, the impact on gene transfer efficiency and immunology of using a vector in a species in which the endogenous virus is prevalent remains unclear.
Although some clinical applications require high levels of transgene expression, other diseases demand a vector system that targets the largest percentage of cells. AAV2, for example, is restricted at transducing only a fraction of mouse hepatocytes, 7 a limitation that can be overcome by the use of alternative capsids such as AAV8.
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AAV2 infection is common in humans, which could impact on applications of AAV-mediated gene transfer in humans. Memory B-cell responses and circulating NAB toward AAV might affect the safety and efficacy of gene therapy in these populations. The impact of pre-existing antibodies on the efficacy of a particular therapeutic approach may depend on the vector capsid, the dose and the route of administration used. In systemic administrations, the presence of NAB, even at low titers, can impact gene transfer efficiency in vivo significantly. 16, 17 Humoral immunity to the AAV capsid also complicates a repeat administration that may be necessary to achieve a long-lasting therapeutic effect (for example, when the target is a self-renewing tissue). In murine and canine animal models, the use of distinct AAV serotypes has been shown to circumvent pre-existing immunity induced by a prior vector administration. 109 A more characterization of the breadth of the antibody response following natural infection and the serological prevalence in human populations is needed to appreciate the complexity of this issue in humans. Evaluation of pooled human Ig from a large human population demonstrated dramatically different neutralization titers for different serotypes, with AAV5 having the highest and AAV4, AAV8 and the caprine AAV the lowest titers. 37 An evaluation of individual sera in global populations has demonstrated a significantly less prevalence of human antibodies of the non-human primate-derived AAV7 and AAV8 compared with human isolate AAV2. Depending on the population, AAV1 either had no or only modest advantage over AAV2 in terms of seroprevalence. Surprisingly, although their seroprevalence was significantly lower, the frequencies of AAV7 and AAV8 positivity may still limit their broad application. AAVrh32.33, a rhesus-derived engineered capsid, was identified in this study to have only a minimal reactivity to human sera. 18 The interface between the capsid and the sensors and mediators of the immune system determines in many aspects the success or failure of the gene transfer. 120, 121 The capsid, together with parameters such as dose and route of administration, can determine the inflammatory fate of the transgene product both on a humoral and a cellular level. The mechanisms underlying this biology are not well understood but often invoke critical interaction with antigen-presentation cells, induction of Tregs and the kinetics and level of transgene expression. Contribution of the innate responses and complement activation toward these observations with different capsid vectors remain largely unexplored. Recently, T-cell responses toward the capsid were deemed responsible for the immunotoxicity and loss of detectable transgene product in a clinical trial of liver-directed gene transfer. 96 The natural biology and earlier exposure to the AAV virus have been proposed to have played a critical role in the recall of a memory T-cell response toward the AAV2 capsid, which affected the success of a human clinical trial. 122 A capsid domain uniquely present on the AAV2 serotype was identified that directs T cells to the capsid. 21 Whether the use of a different serotype will be able to avoid the outcome of the human study remains unclear, largely due to the inability to model the clinical observations in animals.
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Perspectives
The significant advances in AAV capsid identification, characterization, modulation and structural insight generate opportunities that may further the technology to overcome barriers to their successful clinical application. The multitude of natural variants and engineered capsids not only offers great potential but also adds complexity. How does one select the best capsid for a particular application? Can an alternative serotype build on the extensive preclinical and clinical experience generated with AAV2? Is it appropriate to progress with one serotype after years of development, safety and efficacy studies when during that time an improved and more appropriate serotype has been identified? These issues are relevant to any rapidly advancing technology that, at some stage, needs to weigh the potential advantages versus the additional expense in time and resources to characterize and develop a novel AAV. An evaluation in both small and large animal models of a subset of promising vector systems for the relevant modalities that affect safety and efficacy for each particular application can inform a decision on choosing the appropriate AAV to progress clinically. These continuous efforts to improve and optimize should not delay the progress of the field that benefits greatly from the clinical experience with novel AAV vector capsids that is evolving prudently from the bench to the bedside (Table 1 ). Vector decisions are complex but critically important; the authors believe that there is a need for this decision process to be strategized and tailored to the specific requirements of the therapeutic approach. For these strategies to succeed, the need for thorough sets of preclinical data is pivotal. Not only will they guide informed strategic decisions on clinical development but also will further our functional understanding of the capsid and consequently propel more effective vectorengineering strategies.
